Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
Address contributing factors
Cobalamin is a highly active and complex molecule
Bottom line: AOD-9604 offers a targeted, non-stimulant approach to fat loss and metabolic support best suited as a supportive therapy, not a standalone solution
This product is supplied in an encapsulated solid format to support controlled handling, storage, and measurement within laboratory research environments